SLIT and NTRK like family member 5Genealiases: LRRC11 · bA364G4.2
Q-omics provides the consensus-scored SLITRK5 profile across patient tissues and cancer cell-line models. SLITRK5 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SLITRK5 is differentially expressed in 15, with the highest sampling consensus in THCA. Additionally, SLITRK5 RNA expression shows 14,677 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, THCA, and THYM as cancer lineages where SLITRK5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLITRK5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLITRK5 survival associations across molecular data types. SLITRK5 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLITRK5 RNA expression–survival associations across cancer types. High SLITRK5 expression shows unfavorable associations in ACC, KICH, THCA and UCEC, but favorable associations in LGG and KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SLITRK5 RNA expression.
This table summarizes SLITRK5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SLITRK5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLITRK5 shows lower tumor expression in THCA, HNSC, UCEC and STAD and higher tumor expression in KIRC and KIRP. The THCA box plot shows higher SLITRK5 RNA expression in normal versus tumor tissue (log2 FC = −2.015, t-test p < 0.001).
This table shows molecular features associated with SLITRK5 in patient tissues and cancer cell lines. In patient samples, SLITRK5 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLITRK5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
